Assessment of the Relationship between Ki-67 Expression and Different Clinicopathological Factors of Adenoid Cystic Carcinoma: A Retrospective Immunohistochemical Study

ORIGINAL ARTICLE
Mohammed Al Zubidi, Mustafa Mohammed Abdulhussain, Ali Sami Mohsin

 
For citation: Al Zubidi M, Abdulhussain MM, Mohsin AS. Assessment of the Relationship between Ki-67 Expression and Different Clinicopathological Factors of Adenoid Cystic Carcinoma: A Retrospective Immunohistochemical Study. International Journal of Biomedicine. 2025;15(1):141-145. doi:10.21103/Article15(1)_OA14
 
Originally published March 5, 2025

Abstract: 

Background: Adenoid cystic carcinoma (ACC) is an aggressive cancer that can affect many glands in the body, including the salivary glands, lacrimal glands, and upper digestive tract. Although slow growing, ACC has a poor prognosis due to its local invasion as well as elevated recurrence rates. Ki-67 is a widely utilized nuclear indicator, a type of protein found in nature, including cell proliferative immunomarkers. The exact role of Ki-67 remains unclear despite its importance as a predictive and prognostic biomarker. The present study aimed to assess the significance of Ki-67 expression in ACC lesions and their correlation with clinicopathological characteristics.
Methods and Results: Thirty-three histopathology-confirmed ACC cases were included in this study. The expression of Ki67 was evaluated by immunohistochemistry. The immunohistochemical staining revealed brown nuclear positivity of Ki-67 in 33 study samples. Of these, 15(45.5%) had a weak score  (+1), 13(39.4%) - a moderate score  (+2), and 5(15.2%) - a high score  (+3). The distribution of Ki-67 expression according to the grading of ACC lesions was weak and moderately positive for low-grading cases, low positive for moderate-grading cases, and moderately positive for severe-grading cases, with no significant correlation. Regarding the tumor site, the peak incidence for weak, moderate, and high positive staining of Ki-67 expression was at the palate site, followed by the parotid gland and orbit sites, and then the others.
Conclusion: There is a statistical association between Ki-67 level and tumor location parameters. The elevated Ki-67 labeling value relates to poor prognosis.

Keywords: 
adenoid cystic carcinoma • Ki-6 7• immunohistochemistry
References: 
  1. Speight PM, Barrett AW. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. Diagn Histopathol. 2020 Apr 1;26(4):147-58. doi:10.1016/j.mpdhp.2020.01.001
  2. de Morais EF, de Farias Morais HG, de Almeida Freitas R, Coletta RD. Prognostic Significance of Histopathological Parameters for Salivary Gland Adenoid Cystic Carcinoma. Dent J (Basel). 2023 Nov 9;11(11):262. doi: 10.3390/dj11110262. PMID: 37999026; PMCID: PMC10670021.
  3. Atallah S, Casiraghi O, Fakhry N, Wassef M, Uro-Coste E, Espitalier F, Sudaka A, Kaminsky MC, Dakpe S, Digue L, Bouchain O, Morinière S, Hourseau M, Bertolus C, Jegoux F, Thariat J, Calugaru V, Schultz P, Philouze P, Mauvais O, Righini CA, Badoual C, Saroul N, Goujon JM, Marie JP, Taouachi R, Brenet E, Aupérin A, Baujat B. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. Eur J Cancer. 2020 May;130:241-249. doi: 10.1016/j.ejca.2020.01.023. Epub 2020 Mar 11. PMID: 32171628.
  4. Fang Y, Peng Z, Wang Y, Gao K, Liu Y, Fan R, Zhang H, Xie Z, Jiang W. Current opinions on diagnosis and treatment of adenoid cystic carcinoma. Oral Oncol. 2022 Jul;130:105945. doi: 10.1016/j.oraloncology.2022.105945. Epub 2022 Jun 2. PMID: 35662026.
  5. Alsarraj M, Alshehri SM, Qattan A, Mofti A, Wazqer L, Bukhari S, Shamsaldin A, Rajab R. Lymph Node Involvement and the Clinical Stage as Predictors of the Survival of Patients With Adenoid Cystic Carcinoma of the Head and Neck: A Systematic Review and Meta-Analysis. Cureus. 2022 Oct 27;14(10):e30780. doi: 10.7759/cureus.30780. PMID: 36447733; PMCID: PMC9701163.
  6. Hellquist H, Skalova A. Histopathology of the Salivary Glands; Springer: Berlin/Heidelberg, Germany, 2014.
  7. van Weert S, van der Waal I, Witte BI, Leemans CR, Bloemena E. Histopathological grading of adenoid cystic carcinoma of the head and neck: analysis of currently used grading systems and proposal for a simplified grading scheme. Oral Oncol. 2015 Jan;51(1):71-6. doi: 10.1016/j.oraloncology.2014.10.007. Epub 2014 Oct 28. PMID: 25456010.
  8. Morita N, Murase T, Ueda K, Nagao T, Kusafuka K, Nakaguro M, Urano M, Taguchi KI, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Otsuki N, Nibu KI, Inagaki H. Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system. Cancer Sci. 2021 Mar;112(3):1184-1195. doi: 10.1111/cas.14790. Epub 2021 Feb 2. PMID: 33377247; PMCID: PMC7935776.
  9. Dewenter I, Otto S, Kakoschke TK, Smolka W, Obermeier KT. Recent Advances, Systemic Therapy, and Molecular Targets in Adenoid Cystic Carcinoma of the Head and Neck. J Clin Med. 2023 Feb 12;12(4):1463. doi: 10.3390/jcm12041463. PMID: 36835997; PMCID: PMC9967509.
  10. Iyer J, Hariharan A, Cao UMN, Mai CTT, Wang A, Khayambashi P, Nguyen BH, Safi L, Tran SD. An Overview on the Histogenesis and Morphogenesis of Salivary Gland Neoplasms and Evolving Diagnostic Approaches. Cancers (Basel). 2021 Aug 3;13(15):3910. doi: 10.3390/cancers13153910. PMID: 34359811; PMCID: PMC8345412.
  11. de Morais EF, da Silva LP, Moreira DGL, Mafra RP, Rolim LSA, de Moura Santos E, de Souza LB, de Almeida Freitas R. Prognostic Factors and Survival in Adenoid Cystic Carcinoma of the Head and Neck: A Retrospective Clinical and Histopathological Analysis of Patients Seen at a Cancer Center. Head Neck Pathol. 2021 Jun;15(2):416-424. doi: 10.1007/s12105-020-01210-7. Epub 2020 Aug 10. PMID: 32779101; PMCID: PMC8134621.
  12. Bassyoni, Omneya Youssef, Samah Said Elbasateeny, Mahmoud Abdou Yassin, And Taha Abdelwahab Baiomy. Immunohistochemical Expression of Tumour-Associated Macrophage Related Marker (CD68) and Proliferative Marker Ki-67 in Malignant Salivary Glands Tumour: Correlation with the Clinicopathological Factors, Oestrogen Receptor-α and HER-2. J Clin. Diagnostic Res. 2019. 13(10):10-6. doi: 10.7860/JCDR/2019/42392.132 16
  13. Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, Di G, Liu G, Yu K, Shao Z, Wang Z. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020 Jan 14;10(1):225. doi: 10.1038/s41598-019-57094-3. PMID: 31937819; PMCID: PMC6959292.
  14. Wahid SM, Rasul F, Rizvi Z, Nadeem K, Sultan A, Haseeb MT. Immunohistochemical Expression of Ki-67 in Malignant Salivary Gland Tumors. J Islamabad Med Dental Coll. 2024; 13(1): 143-150. doi: 10.35787/jimdc.v13i1.886.
  15. Takebayashi S, Shinohara S, Tamaki H, Tateya I, Kitamura M, Mizuta M, Tanaka S, Kojima T, Asato R, Maetani T, Ushiro K, Kitani Y, Ichimaru K, Honda K, Yamada K, Omori K. Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol. 2018 Jan;138(1):73-79. doi: 10.1080/00016489.2017.1371329. Epub 2017 Sep 12. PMID: 28899226.
  16. Rasul F, Wahid SM, Imran I, Rizvi Z, Jaffar R, Anwar A. Immunohistochemical Expression of BCL-2 in Malignant Salivary Gland Tumors. J Islamabad Med Dent College 2021 Mar 31;10(1):15-22. doi: 10.35787/jimdc.v10i1.542
  17. Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G, Adamo V. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLoS One. 2015 Jun 3;10(6):e0128368. doi: 10.1371/journal.pone.0128368. Erratum in: PLoS One. 2015 Jul 02;10(7):e0132647. doi: 10.1371/journal.pone.0132647. PMID: 26039245; PMCID: PMC4454487.
  18. Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Michele C, Tuccari G, Adamo V. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget. 2017 Aug 16;8(44):76974-76986. doi: 10.18632/oncotarget.20293. Erratum in: Oncotarget. 2019 Jan 25;10(8):917. doi: 10.18632/oncotarget.26650. PMID: 29100362; PMCID: PMC5652756.
  19. Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA, Douzinas EE, Patsouris E. Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005 Mar;41(3):328-35. doi: 10.1016/j.oraloncology.2004.12.004. PMID: 15743696.
  20. Dewenter I, Otto S, Kakoschke TK, Smolka W, Obermeier KT. Recent Advances, Systemic Therapy, and Molecular Targets in Adenoid Cystic Carcinoma of the Head and Neck. J Clin Med. 2023 Feb 12;12(4):1463. doi: 10.3390/jcm12041463. PMID: 36835997; PMCID: PMC9967509.
  21. Chia N, Petersson F. Adenoid cystic carcinoma with dedifferentiation/expansion of the luminal cell component and preserved biphasic morphology - Early high-grade transformation. Ann Diagn Pathol. 2021 Feb;50:151650. doi: 10.1016/j.anndiagpath.2020.151650. Epub 2020 Oct 24. PMID: 33254086.
  22. Esmail EB, El-rashidy MA, Mashhour HA, Abo-Safia HS. Evaluation of the clinicopathological significance of E-Cadherin and Ki 67 immuno-expression in triple negative breast cancer. Egyptian Journal of Cancer and Biomedical Research. 2023 Mar 1;7(1):55-67. doi: 10.21608/jcbr.2023.181487.1287
  23. Jaber MA, Hassan M, Ingafou M, Elameen AM. Adenoid Cystic Carcinoma of the Minor Salivary Glands: A Systematic Review and Meta-Analysis of Clinical Characteristics and Management Strategies. J Clin Med. 2024 Jan 3;13(1):267. doi: 10.3390/jcm13010267. PMID: 38202273; PMCID: PMC10779762.
  24. Lee RH, Wai KC, Chan JW, Ha PK, Kang H. Approaches to the Management of Metastatic Adenoid Cystic Carcinoma. Cancers (Basel). 2022 Nov 20;14(22):5698. doi: 10.3390/cancers14225698. PMID: 36428790; PMCID: PMC9688467.
  25. Dewenter I, Otto S, Kakoschke TK, Smolka W, Obermeier KT. Recent Advances, Systemic Therapy, and Molecular Targets in Adenoid Cystic Carcinoma of the Head and Neck. J Clin Med. 2023 Feb 12;12(4):1463. doi: 10.3390/jcm12041463. PMID: 36835997; PMCID: PMC9967509.
  26. Zhou M, Ma T, Wang X, Zhang S, Yang G, Song R, Chen X. High-risk subtype: Clinical manifestations and molecular characteristics of submandibular gland adenoid cystic carcinoma. Front Oncol. 2022 Dec 16;12:1021169. doi: 10.3389/fonc.2022.1021169. PMID: 36591454; PMCID: PMC9800506.

Download Article
Received January 16, 2025.
Accepted February 25, 2025.
©2025 International Medical Research and Development Corporation.